Press Release: CytoMed Therapeutics Announces China Research Collaboration to Enhance its Allogeneic CAR γδ T In Vivo Persistency

CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based immunotherapies for the treatment of various cancers, announces today that it signed a Memorandum of Understanding (MOU) with Hangzhou CNK Therapeutics Co., Ltd (CNK).

Log In or Register as a healthcare professional to read the full article.

Share via

Also worth reading

People also read:

What Exactly is Neuroblastoma?

Neuroblastoma is a complex childhood cancer that demands our attention. This article provides a detailed exploration of neuroblastoma, including its origins, symptoms, diagnostic procedures, treatment methods, and prognosis.

Read More »